HDAC Inhibitor Modulation of Histone Acetylation for Bone Destruction Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments are inadequate for addressing bone destruction associated with cancers such as multiple myeloma, breast cancer, and prostate cancer, which disrupt the balance between osteolytic and bone-forming activities.
Innovation Solution
The use of the HDAC inhibitor N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)-ethyl]-amino]methyl]phenyl]-2E-2-propenamide or its pharmaceutically acceptable salt to treat and prevent bone destruction by modulating histone acetylation levels, thereby regulating gene expression and cellular responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for bone destruction associated with cancer, then some level of treatment is provided, but the treatments are inadequate and fail to effectively address bone destruction
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of HDAC inhibitors (specifically using the compound N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)-ethyl]-amino]methyl]phenyl]-2E-2-propenamide) to enhance their effectiveness against bone destruction. This structural parameter change enables the inhibitor to specifically target osteoclast differentiation and bone resorption pathways, providing reliable treatment across multiple cancer types including multiple myeloma, breast cancer, and prostate cancer.
2Strength
If HDAC inhibitors are used to treat bone destruction, then bone density increases and tumor burden decreases, but the mechanism requires precise regulation of histone acetylation levels
Solution Approach 1:
The patent uses HDAC inhibitors as intermediary molecules that mediate between gene expression regulation and osteoclast function. The compound specifically inhibits HDAC enzymes, leading to hyperacetylation of histones and altered gene expression patterns in osteoclasts. This intermediary mechanism effectively increases bone density by reducing osteoclast-mediated bone resorption without requiring direct manipulation of complex bone remodeling pathways.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Significantly reduces tumor burden, increases trabecular and cortical bone density, and extends the time to clinical endpoint in animal models, demonstrating effective treatment and prevention of bone destruction in these cancers.
Implementation Method 1
Reversible acetylation of histones is a major regulator of gene expression that acts by altering accessibility of transcription factors to DNA. In normal cells, histone deacetylase (HDAC) and histone acetyltransferase together control the level of acetylation of histones to maintain a balance. Inhibition of HDAC results in the accumulation of hyperacetylated histones, which results in a variety of cellular responses.
Data Source
Figure 1A~1D
Figure 2A~2D
Figure 3
AI summary
The present invention relates to the use of HDAC inhibitors for the treatment of bone destruction caused by cancer, inflammatory diseases and osteoporosis.